Rua Bioscience IPO: stretching the runway

Rua Bioscience IPO: stretching the runway
Brent Melville
Medicinal cannabis firm Rua Bioscience had planned to list on the NZX in May, but then covid came along and upset the apple cart.“The process was well advanced, we were about halfway with the regulatory and product disclosure processes in February already, and then we had no real option but to press pause,” chair Trevor Burt told BusinessDesk.Last week Rua rekindled its $20 million initial public offering, announcing it will offer 40 million shares at 50 cents a share to the market, representing 28.6 percent of 140 million shares on...